RxDoctor Payments Data

Susan Avery, MD

Adult Medicine · Great Falls, MTNPI 1437244845

Payments from drug & device makers

$2,107in general payments, 2019–2025

Across 91 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$444
  • AbbVie$197
  • Merck$196
  • Exact Sciences$174
  • Lilly USA, LLC$162
  • Pfizer$144
  • plus $789 from 14 others

What the payments were for

  • Food & beverage$2,04297%
  • Education$653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult medicine providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$99,578
Medicare patients
239
Services billed
901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$69,621
OzempicSemaglutide36$51,931
FarxigaDapagliflozin Propanediol29$41,901
Invega SustennaPaliperidone Palmitate12$39,121
MounjaroTirzepatide24$38,490
JanuviaSitagliptin Phosphate25$30,818
JardianceEmpagliflozin22$30,185
Tresiba Flextouch U-100Insulin Degludec25$17,257
XareltoRivaroxaban18$17,107
Combivent RespimatIpratropium/Albuterol Sulfate13$14,415
Breo ElliptaFluticasone/Vilanterol22$8,707
Spiriva HandihalerTiotropium Bromide12$6,882
Levothyroxine Sodium454$4,170
Estradiol42$4,061
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$144$72,47984 claims
Novo NordiskOzempic$444$51,93136 claims
Boehringer IngelheimJardiance, Combivent Respimat$73$44,59935 claims
AstraZenecaFarxiga$113$41,90129 claims
Lilly USA, LLCMounjaro$162$38,49024 claims
MerckJanuvia$196$30,81825 claims
GSKBreo Ellipta$118$8,70722 claims
AbbVieSynthroid, Armour Thyroid$197$4,13353 claims
Sanofi-aventis U.S. LLCLantus$31$1,13416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other adult medicine in Great Falls

Where these figures come from

Is this you, or does something look wrong? →